Graig Suvannavejh
Stock Analyst at Mizuho
(2.20)
# 2,670
Out of 4,843 analysts
147
Total ratings
42.34%
Success rate
-5.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $12 → $11 | $3.78 | +191.01% | 2 | May 20, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $30 → $26 | $7.24 | +259.12% | 5 | May 16, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $44 → $48 | $34.50 | +39.13% | 18 | May 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $20 | $16.93 | +18.13% | 7 | May 14, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $7 → $8 | $5.15 | +55.34% | 7 | May 14, 2025 | |
| IMCR Immunocore Holdings | Maintains: Neutral | $38 → $33 | $36.50 | -9.59% | 8 | Apr 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $212 → $216 | $105.16 | +105.40% | 21 | Mar 27, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Outperform | $3 → $1.5 | $0.29 | +412.82% | 2 | Nov 27, 2024 | |
| AUTL Autolus Therapeutics | Upgrades: Buy | $7 → $7.6 | $1.75 | +334.29% | 1 | Nov 18, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Outperform | $74 | $7.42 | +897.30% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $0.5 | $0.31 | +60.00% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $56.07 | -12.61% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $19.89 | +151.38% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $0.72 | +2,692.13% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $82 | $69.73 | +17.60% | 6 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $5.39 | +196.85% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $22 | $2.22 | +893.23% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $8 | $1.71 | +367.84% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $3.11 | +221.54% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $1.33 | +576.69% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $1.18 | +5,323.73% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $3.60 | -72.25% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.89 | +90.11% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $61.33 | -42.93% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $3.41 | +134.60% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $31.02 | +83.75% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $35.11 | -85.76% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $6.25 | +443.90% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $3.76 | +644.68% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $14.28 | +117.09% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $0.20 | +9,404.75% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.16 | +119.91% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $13.04 | +176.07% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $28.76 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.89 | +4,076.54% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $108.07 | +18.44% | 1 | Sep 14, 2020 |
Corvus Pharmaceuticals
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $3.78
Upside: +191.01%
EyePoint Pharmaceuticals
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $7.24
Upside: +259.12%
Harmony Biosciences Holdings
May 15, 2025
Maintains: Outperform
Price Target: $44 → $48
Current: $34.50
Upside: +39.13%
Apellis Pharmaceuticals
May 14, 2025
Maintains: Neutral
Price Target: $30 → $20
Current: $16.93
Upside: +18.13%
Amylyx Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.15
Upside: +55.34%
Immunocore Holdings
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $36.50
Upside: -9.59%
Axsome Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $105.16
Upside: +105.40%
Adaptimmune Therapeutics
Nov 27, 2024
Maintains: Outperform
Price Target: $3 → $1.5
Current: $0.29
Upside: +412.82%
Autolus Therapeutics
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.75
Upside: +334.29%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $7.42
Upside: +897.30%
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.31
Upside: +60.00%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $56.07
Upside: -12.61%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $19.89
Upside: +151.38%
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $0.72
Upside: +2,692.13%
Jun 7, 2024
Maintains: Buy
Price Target: $36 → $82
Current: $69.73
Upside: +17.60%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $5.39
Upside: +196.85%
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $2.22
Upside: +893.23%
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $1.71
Upside: +367.84%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $3.11
Upside: +221.54%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $1.33
Upside: +576.69%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $1.18
Upside: +5,323.73%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $3.60
Upside: -72.25%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $7.89
Upside: +90.11%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $61.33
Upside: -42.93%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $3.41
Upside: +134.60%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $31.02
Upside: +83.75%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $35.11
Upside: -85.76%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $6.25
Upside: +443.90%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $3.76
Upside: +644.68%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $14.28
Upside: +117.09%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $0.20
Upside: +9,404.75%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.16
Upside: +119.91%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $13.04
Upside: +176.07%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $28.76
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.89
Upside: +4,076.54%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $108.07
Upside: +18.44%